ENTRY OF STAVUDINE INTO CEREBROSPINAL FLUID OF HIV INFECTED SUBJECTS
ENTRY OF STAVUDINE INTO CEREBROSPINAL FLUID OF HIV INFECTED SUBJECTS
批准号:
6274547
负责人:
ROB R MCGREGOR
金额:
$2.5万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-04-15 至 1998-11-30
中文摘要
司他夫定是一种有效的HIV-1逆转录酶抑制剂,
1994.未对脑脊液司他夫定进行系统评价
已报告浓度,无论是单次给药或
稳态条件。提高对司他夫定渗透性的认识
由于需要足够的抑制剂,
在中枢神经系统中的浓度,以抑制艾滋病毒复制
希望能预防或减缓艾滋病痴呆症的发展
复杂.
本方案将检查司他夫定(d4 T)在
接受择期手术的HIV感染者的脑脊液(CSF)
腰椎穿刺(LP)。 将研究两组受试者:1)
那些出于临床考虑而开司他夫定的人,他们将提供
了解稳态条件下达到的CSF浓度;
2)那些没有接受司他夫定临床,但同意采取
计划LP前单次给药,将提供以下信息
急性动力学。
这项研究还将确定是否存在关系
患者CD 4细胞浓度与CSF司他夫定的疗效之间的关系
条目以及CSF白色细胞之间是否存在关系
浓度或总蛋白和CSF司他夫定的效率
入境
英文摘要
Stavudine is a potent HIV-1 reverse transcriptase inhibitor licensed in
1994. No systematic evaluation of cerebrospinal fluid stavudine
concentrations has been reported, either for single doses or under
steady-state conditions. Improved understanding of stavudine penetration
into CSF is important because of the desire for adequate inhibitory
concentrations in the central nervous system to suppress HIV replication
and hopefully to prevent or slow the development of the AIDS dementia
complex.
This protocol will examine the concentrations of stavudine (d4T) in
cerebrospinal fluid (CSF) of HIV-infected subjects undergoing elective
lumbar punctures (LP). Two groups of subjects will be studied: 1)
those prescribed stavudine for clinical considerations, who will provide
insight into CSF concentrations achieved under steady-state conditions;
2) those not receiving stavudine clinically, but agreeing to take a
single dose prior to a scheduled LP, who will provide information on
acute dynamics.
This study will also determine whether or not a relationship exists
between patient CD4 cell concentration and efficiency of CSF stavudine
entry and whether or not a relationship exists between CSF white cell
concentration or total protein and the efficiency of CSF stavudine
entry.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GENEVAX-HIV (APL 400-003) CANDIDATE DNA VACCINE--PILOT DOSE
-
批准号:6565843
-
项目类别:
-
资助金额:$12.41万
-
财政年份:2001
-
负责人:ROB R MCGREGOR
-
依托单位:
GENEVAX-HIV (APL 400-003) CANDIDATE DNA VACCINE--PILOT DOSE
-
批准号:6468093
-
项目类别:
-
资助金额:$12.41万
-
财政年份:2000
-
负责人:ROB R MCGREGOR
-
依托单位:
GENEVAX-HIV (APL 400-003) CANDIDATE DNA VACCINE--PILOT DOSE
-
批准号:6303412
-
项目类别:
-
资助金额:$2.51万
-
财政年份:1999
-
负责人:ROB R MCGREGOR
-
依托单位:
ACTG 313--PHASE II TRIAL OF MEGESTROL ACETATE AND TESTOSTERONE
-
批准号:6274544
-
项目类别:
-
资助金额:$2.5万
-
财政年份:1998
-
负责人:ROB R MCGREGOR
-
依托单位:
ACTG 368--INDINAVIR SULFATE, DMP266, & 1592U89 IN HIV INFECTED SUBJECTS
-
批准号:6274553
-
项目类别:
-
资助金额:$2.5万
-
财政年份:1998
-
负责人:ROB R MCGREGOR
-
依托单位:
GENEVAX-HIV (APL 400-003) CANDIDATE DNA VACCINE--PILOT DOSE
-
批准号:6113295
-
项目类别:
-
资助金额:$2.51万
-
财政年份:1998
-
负责人:ROB R MCGREGOR
-
依托单位:
ACTG 323--FLUCONAZOLE AS CHRONIC SUPPRESSIVE THERAPY VS EPISODIC THERAPY
-
批准号:6274540
-
项目类别:
-
资助金额:$2.5万
-
财政年份:1998
-
负责人:ROB R MCGREGOR
-
依托单位:
GENEVAX-HIV (APL 400-003) CANDIDATE DNA VACCINE--PILOT DOSE
-
批准号:6274529
-
项目类别:
-
资助金额:$2.5万
-
财政年份:1998
-
负责人:ROB R MCGREGOR
-
依托单位:
ACTG 362
-
批准号:6274563
-
项目类别:
-
资助金额:$2.5万
-
财政年份:1998
-
负责人:ROB R MCGREGOR
-
依托单位:
海外基金